Kaylie Johnson has been leading the Global Biomarker Development Program (BDP) since joining MSK in 2020. The MSK Global BDP aims to change the paradigm of collaborative biomarker development research by providing a platform for faculty to engage with industry and biotechnology leaders who are scientifically aligned. The ultimate goal of research collaborations pursued by the MSK Global BDP are centered around enhancing clinical decision making and improving patient outcomes. In addition to managing the MSK Global BDP, Kaylie is operationalizing the international research and development (R&D) strategy set forth by MSK faculty leaders.

Prior to joining MSK, Kaylie held roles at NYU Langone Health and Massachusetts General Hospital as a research administrator.